Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales

LeqembiNegative

AI Analysis

Summary

Biogen is looking to products from its Apellis deal to offset disappointing Leqembi sales since the Alzheimer's drug's approval in 2023. The article discusses Biogen CEO Chris Viehbacher's strategy to supplement revenue amid slower-than-expected commercial uptake.

Importance:4/10

Sentiment:

-0.40

commercial_performanceAlzheimer'spartnershipsales_concerns

Related Companies

$BIIB $ESALY $APLS

Read the original article

Published by Endpoints News on July 23, 2026 2:00 PM

Read Original